BBBT (Black Bird Biotech) Liabilities-to-Assets : 10.24 (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Black Bird Biotech Liabilities-to-Assets?

Black Bird Biotech BBBT -99.00% Liabilities-to-Assets is 10.24 as of Sep. 2023.

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Black Bird Biotech's Total Liabilities for the quarter that ended in Sep. 2023 was $1.02 Mil. Black Bird Biotech's Total Assets for the quarter that ended in Sep. 2023 was $0.10 Mil. Therefore, Black Bird Biotech's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2023 was 10.24.

Black Bird Biotech  (OTCPK:BBBT) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.

Black Bird Biotech Liabilities-to-Assets Related Terms

Black Bird Biotech Liabilities-to-Assets Historical Data

* Premium members only.

The historical data trend for Black Bird Biotech's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Black Bird Biotech Liabilities-to-Assets Chart

Black Bird Biotech Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Liabilities-to-Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,173.45 0.78 0.13 3.96 3.97

Black Bird Biotech Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.87 3.96 4.77 9.11 10.24

BBBT vs BLMS, INLB, CENBF: Liabilities-to-Assets Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Black Bird Biotech's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Black Bird Biotech Liabilities-to-Assets vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Black Bird Biotech's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Black Bird Biotech's Liabilities-to-Assets falls into.


Black Bird Biotech Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Black Bird Biotech's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Liabilities-to-Assets (A: Dec. 2022 )=Total Liabilities/Total Assets
=0.868678/0.219508
=3.96

Black Bird Biotech's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2023 is calculated as

Liabilities-to-Assets (Q: Sep. 2023 )=Total Liabilities/Total Assets
=1.021557/0.099779
=10.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Liabilities-to-Assets →
What does a Liabilities-to-Assets of 10.24 mean?
Black Bird Biotech (BBBT) has a Liabilities-to-Assets of 10.24 as of Sep. 2023. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Black Bird Biotech and its competitors.
Is Black Bird Biotech's Liabilities-to-Assets too high?
Black Bird Biotech's current Liabilities-to-Assets is 10.24.
How does Black Bird Biotech's Liabilities-to-Assets compare to BLMS and INLB?
Black Bird Biotech's Liabilities-to-Assets of 10.24 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Drug Manufacturers company?
A good Liabilities-to-Assets depends on the Drug Manufacturers industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Black Bird Biotech and its competitors. Black Bird Biotech's current Liabilities-to-Assets is 10.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Black Bird Biotech stock overvalued right now?
Black Bird Biotech (BBBT) has a current Liabilities-to-Assets of 10.24. The current Liabilities-to-Assets is 10.24. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Black Bird Biotech (BBBT), the current Liabilities-to-Assets is 10.24 as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Black Bird Biotech Business Description

Address 2801 E Camelback Road, Suite 200, Phoenix, AZ, USA, 85016
Black Bird Biotech Inc is a licensed grower of industrial hemp under the Montana Hemp Pilot Program. In addition, it is the distributor in the U. S. and Canada for MiteXstream, an EPA-registered plant-based biopesticide effective in the eradication of spider mites, a pest that destroys crops, especially cannabis, hops, coffee, and house plants, as well as molds and mildew. Its products include MiteXstream Biopesticide, Grizzly Creek Naturals, and Black Bird American Hemp.